- Brief Report
- Published:
Memantine for prevention of migraine: a retrospective study of 60 cases
The Journal of Headache and Pain volume 8, pages 248–250 (2007)
Abstract
The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.
References
Sanchez-Del-Rio M, Reuter U et al (2006) New insights into migraine pathophysiology. Curr Opin Neurol 19:294–298
Chen HS, Pellegrini JW, Aggarwal SK et al (1992) Open-channel block of Nmethyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12:4427–4436
Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14:135–146
Chen HS, Lipton SA (2006) The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 97:1611–1626
Peeters M, Gunthorpe MJ, Strijbos PJ et al (2007) Effects of pan-and subtype-selective NMDA receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther 321:564–572
Aracava Y, Pereira EF, Maelicke A et al (2005) Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312:1195–1205
Rammes G, Rupprecht R, Ferrari U et al (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkylcyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a noncompetitive manner. Neurosci Lett 306:81–84
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Charles, A., Flippen, C., Romero Reyes, M. et al. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 8, 248–250 (2007). https://doi.org/10.1007/s10194-007-0406-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10194-007-0406-7